A randomized controlled trial of an intensive insulin regimen in patients with hyperglycemic acute lymphoblastic leukemia

Clinical Lymphoma, Myeloma and Leukemia

Volumn 12, Issue 5, 2012, Pages 355-362

  Vu, Khanh ^a   Busaidy, Naifa ^a   Cabanillas, Maria E ^a   Konopleva, Marina ^a   Faderl, Stefan ^a   Thomas, Deborah A ^a   O'Brien, Susan ^a   Broglio, Kristine ^a   Ensor, Joe ^a   Escalante, Carmen ^a   Andreeff, Michael ^a   Kantarjian, Hagop ^a   Lavis, Victor ^a   Yeung, Sai Ching Jim ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Diabetes; Intensive insulin regimen; Metformin; Secretagogues; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; C PEPTIDE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; GLUCOSE; INSULIN ASPART; INSULIN GLARGINE; METFORMIN; METHOTREXATE; METHYLPREDNISOLONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BURKITT LYMPHOMA; CANCER REGRESSION; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; LYMPHOBLASTOMA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SECONDARY ANALYSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD GLUCOSE; BURKITT LYMPHOMA; C-PEPTIDE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN, LONG-ACTING; MALE; METFORMIN; MIDDLE AGED; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; PROSPECTIVE STUDIES; THIAZOLIDINEDIONES; TREATMENT OUTCOME; VINCRISTINE; YOUNG ADULT;

EID: 84867424051     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2012.05.004     Document Type: Article

References (33)

1. T.I. Nilsen, L.J. Vatten Prospective study of colorectal cancer risk and physical activity, diabetes, blood glucose and BMI: exploring the hyperinsulinaemia hypothesis Br J Cancer 84 2001 417 422
2. G. Verlato, G. Zoppini, E. Bonora Mortality from site-specific malignancies in type 2 diabetic patients from Verona Diabetes Care 26 2003 1047 1051
3. L.C. Richardson, L.A. Pollack Therapy insight: influence of type 2 diabetes on the development, treatment and outcomes of cancer Nat Clin Pract Oncol 2 2005 48 53
4. S.S. Coughlin, E.E. Calle, L.R. Teras Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults Am J Epidemiol 159 2004 1160 1167
5. L.V. van de Poll-Franse, S. Houterman, M.L. Janssen-Heijnen Less aggressive treatment and worse overall survival in cancer patients with diabetes: a large population based analysis Int J Cancer 120 2007 1986 1992
6. H.M. Kantarjian, S. O'Brien, T.L. Smith Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia J Clin Oncol 18 2000 547 561
7. M.A. Weiser, M.E. Cabanillas, M. Konopleva Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen Cancer 100 2004 1179 1185
8. G.E. Umpierrez, S.D. Isaacs, N. Bazargan Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes J Clin Endocrinol Metab 87 2002 978 982
9. M. Laakso Hyperglycemia and cardiovascular disease in type 2 diabetes Diabetes 48 1999 937 942
10. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus JAMA 287 2002 2563 2569
11. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus The Diabetes Control and Complications Trial Research Group N Engl J Med 329 1993 977 986
12. R.R. Holman, S.K. Paul, M.A. Bethel 10-Year follow-up of intensive glucose control in type 2 diabetes N Engl J Med 359 2008 1577 1589
13. D.M. Nathan, P.A. Cleary, J.Y. Backlund Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes N Engl J Med 353 2005 2643 2653
14. G. van den Berghe, P. Wouters, F. Weekers Intensive insulin therapy in the critically ill patients N Engl J Med 345 2001 1359 1367
15. K. Vu, S.C. Yeung, D.A. Thomas Effect of tight control of blood glucose during hyper-CVAD chemotherapy for acute lymphocytic leukemia Blood 112 2008 336
16. D.A. Thomas, S. O'Brien, J.L. Jorgensen Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia Blood 113 2009 6330 6337
17. X. Chen, T.O. Scholl Ethnic differences in C-peptide/insulin/glucose dynamics in young pregnant women J Clin Endocrinol Metab 87 2002 4642 4646
18. J. Boren, M. Cascante, S. Marin Gleevec (STI571) influences metabolic enzyme activities and glucose carbon flow toward nucleic acid and fatty acid synthesis in myeloid tumor cells J Biol Chem 276 2001 37747 37753
19. J.D. Bagdade, R.K. Root, R.J. Bulger Impaired leukocyte function in patients with poorly controlled diabetes Diabetes 23 1974 9 15
20. S.M. Gapstur, P.H. Gann, L.A. Colangelo Postload plasma glucose concentration and 27-year prostate cancer mortality (United States) Cancer Causes Control 12 2001 763 772
21. P.J. Goodwin, M. Ennis, K.I. Pritchard Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study J Clin Oncol 20 2002 42 51
22. J.A. Meyerhardt, P.J. Catalano, D.G. Haller Impact of diabetes mellitus on outcomes in patients with colon cancer J Clin Oncol 21 2003 433 440
23. Y.H. Feng, G. Velazquez-Torres, C. Gully The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth J Cell Mol Med 15 2011 825 836
24. R.J. Dowling, M. Zakikhani, I.G. Fantus Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells Cancer Res 67 2007 10804 10812
25. M. Buzzai, R.G. Jones, R.K. Amaravadi Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth Cancer Res 67 2007 6745 6752
26. A. Isakovic, L. Harhaji, D. Stevanovic Dual antiglioma action of metformin: cell cycle arrest and mitochondria-dependent apoptosis Cell Mol Life Sci 64 2007 1290 1302
27. L.W. Wang, Z.S. Li, D.W. Zou Metformin induces apoptosis of pancreatic cancer cells World J Gastroenterol 14 2008 7192 7198
28. M.H. Fenner, E. Elstner Peroxisome proliferator-activated receptor-gamma ligands for the treatment of breast cancer Expert Opin Investig Drugs 14 2005 557 568
29. B.E. Lyles, T.O. Akinyeke, P.E. Moss Thiazolidinediones regulate expression of cell cycle proteins in human prostate cancer cells via PPARgamma-dependent and PPARgamma-independent pathways Cell Cycle 8 2009 268 277
30. Y.W. Dong, X.P. Wang, K. Wu Suppression of pancreatic carcinoma growth by activating peroxisome proliferator-activated receptor gamma involves angiogenesis inhibition World J Gastroenterol 15 2009 441 448
31. E. Papageorgiou, N. Pitulis, M. Manoussakis Rosiglitazone attenuates insulin-like growth factor 1 receptor survival signaling in PC-3 cells Mol Med 14 2008 403 411
32. G. Cantini, A. Lombardi, E. Piscitelli Rosiglitazone inhibits adrenocortical cancer cell proliferation by interfering with the IGF-IR intracellular signaling PPAR Res 2008 2008 90404
33. R.E. Teresi, C.W. Shaiu, C.S. Chen Increased PTEN expression due to transcriptional activation of PPARgamma by lovastatin and rosiglitazone Int J Cancer 118 2006 2390 2398